Dental products company Envista Holdings (NYSE:NVST) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.1% year on year to $616.9 million. Its non-GAAP profit of $0.24 per share was 17.1% above analysts’ consensus estimates.
Is now the time to buy NVST? Find out in our full research report (it’s free).
Envista (NVST) Q1 CY2025 Highlights:
- Revenue: $616.9 million vs analyst estimates of $608.3 million (1.1% year-on-year decline, 1.4% beat)
- Adjusted EPS: $0.24 vs analyst estimates of $0.20 (17.1% beat)
- Adjusted EBITDA: $79 million vs analyst estimates of $76.37 million (12.8% margin, 3.4% beat)
- Management reiterated its full-year Adjusted EPS guidance of $1 at the midpoint
- Operating Margin: 6.3%, down from 7.7% in the same quarter last year
- Free Cash Flow was -$5.6 million, down from $29.3 million in the same quarter last year
- Constant Currency Revenue was flat year on year, in line with the same quarter last year
- Market Capitalization: $3.07 billion
StockStory’s Take
Envista’s first-quarter results were shaped by steady demand across most of its dental portfolio, with management highlighting operational progress in consumables, premium implants, and orthodontics outside China. CEO Paul Keel noted, “We delivered core growth of 0.2% and adjusted EBITDA margin around 13%, both in line with our expectations,” while emphasizing that the company’s broad-based business model helped offset regional and product-specific headwinds. Management attributed the slight year-over-year sales decline to unfavorable foreign exchange rates and two fewer billing days, with price increases and productivity gains partially mitigating these factors.
Looking ahead, management reiterated its full-year profit guidance, but addressed wider risks tied to ongoing tariff changes and macroeconomic uncertainty. The company’s leadership discussed efforts to offset tariff impacts by shifting supply chains and increasing pricing where possible. Keel acknowledged, “We are maintaining our 2025 guidance… albeit with a wider confidence interval for the reasons just mentioned,” and stressed that dental remains a relatively stable industry but is not immune to consumer confidence trends or cost inflation.
Key Insights from Management’s Remarks
Envista’s management focused on the impact of external pressures and the company’s operational agility in navigating a complex global environment, while also highlighting strategic initiatives underway.
-
Tariff Mitigation Efforts: Management described the creation of a dedicated tariff task force and detailed supply chain adjustments, including shifting manufacturing of premium implants from the U.S. to Sweden for the Chinese market and qualifying additional suppliers to diversify risk. These actions are intended to offset costs from new and potential tariffs between the U.S., China, and Europe.
-
Segment Growth Drivers: Growth was reported in consumables, premium implants, and orthodontics outside China, with strong customer service levels and productivity improvements. Management cited stable performance in North America, Japan, and emerging markets, and noted that flat European results reflected broader market conditions.
-
Operational Efficiency Initiatives: The company achieved record Spark unit cost reductions and improved general and administrative (G&A) productivity, supported by restructuring and ongoing cost control measures. These operational gains were credited with helping to offset foreign exchange and margin pressures.
-
China VBP (Volume-Based Procurement) Developments: Management explained that the implementation of VBP in China’s orthodontics market is proceeding as anticipated, with expectations for a soft first half followed by benefits in the second half if market share consolidates as happened in prior implant tenders.
-
People and Leadership Updates: Envista reported a notable increase in employee engagement and retention, attributing some of the progress to recent leadership changes and a blend of industry experience with new perspectives from other sectors. These people-focused efforts are seen as foundational to maintaining execution during uncertain times.
Drivers of Future Performance
Management’s outlook for the remainder of the year is centered on the successful mitigation of tariff impacts, steady demand for non-elective dental procedures, and ongoing cost reduction initiatives, balanced against macroeconomic headwinds.
-
Tariff and Supply Chain Flexibility: Envista’s ability to shift manufacturing locations and qualify new suppliers is expected to help offset the cost of current tariffs, but management noted that the environment remains fluid and risks of further changes persist.
-
China VBP and Market Consolidation: The timing and outcome of Volume-Based Procurement in China will be pivotal, especially for orthodontics, as management anticipates a recovery in the second half if the company can capture additional volume as larger players did during previous VBP cycles.
-
Operational Productivity and Pricing Strategy: Further gains in Spark margin, continued G&A productivity, and price realization are set to drive profitability. However, management cautioned that pricing power varies by geography and product, with greater sensitivity in U.S. markets and commodity categories.
Top Analyst Questions
- Jon Block (Stifel): Asked for specifics on tariff exposure and mitigation, to which CEO Paul Keel detailed supply chain shifts and supplier diversification, emphasizing ongoing adjustments as the environment evolves.
- Jason Bednar (Piper Sandler): Probed the net impact of tariffs and the confidence in mitigation, with management stating guidance incorporates current tariffs but confidence is "less certain" due to volatility, and that outcomes in the second half depend on successful execution of planned actions.
- Elizabeth Anderson (Evercore ISI): Queried expectations and guidance assumptions for China’s Volume-Based Procurement, with Keel confirming the process is tracking expectations and projecting a benefit in the second half as market share consolidates.
- Jeff Johnson (Baird): Sought clarity on price realization as a tariff mitigation strategy, prompting Keel to outline that pricing power is strongest in differentiated products and weaker in commodity segments, especially in the U.S.
- Allen Lutz (Bank of America): Asked about the performance divergence between premium and Challenger implants, with management attributing Challenger’s softness to fewer billing days and stating there is no expected change to its long-term growth trajectory.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) Envista’s execution of supply chain shifts and tariff mitigation strategies, (2) progress and volume gains from China’s Volume-Based Procurement in orthodontics, and (3) further improvements in Spark margins and overall cost productivity. Additionally, we will track management’s ability to sustain price realization in competitive and cost-sensitive markets, especially in light of macroeconomic pressures.
Envista currently trades at a forward P/E ratio of 17.7×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report.
High-Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.